Changing the History of Prostate Cancer with New Targeted Therapies

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted therapies for the treatment of different molecular subtypes. Some biomarkers are described as potential molecular targets different from classic androgen receptors (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernando Polo, Susana, Moreno Muñoz, Diana, Rosero Rodríguez, Adriana Carolina, Silva Ruiz, Jorge, Rosero Rodríguez, Diana Isabel, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067446/
https://www.ncbi.nlm.nih.gov/pubmed/33917592
http://dx.doi.org/10.3390/biomedicines9040392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067446/
https://www.ncbi.nlm.nih.gov/pubmed/33917592
http://dx.doi.org/10.3390/biomedicines9040392

Ejemplares similares